Page last updated: 2024-09-03

imatinib mesylate and Acquired Immune Deficiency Syndrome

imatinib mesylate has been researched along with Acquired Immune Deficiency Syndrome in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bonnie, G; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Medina, J; Rios, A; Tsimberidou, AM	1
Senior, K	1
Boveri, E; Chichino, G; Cilloni, D; Daniela, C; Emanuela, B; Enrico, G; Giovanni, M; Gottardi, E; Guido, C; Martinelli, G; Merante, S; Serena, M; Simona, S; Soverini, S	1

Reviews

1 review(s) available for imatinib mesylate and Acquired Immune Deficiency Syndrome

Article	Year
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leukemia research, 2004, Volume: 28, Issue:6 Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Benzamides; Cytogenetic Analysis; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004

Article

Year

Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.

Leukemia research, 2004, Volume: 28, Issue:6

Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Benzamides; Cytogenetic Analysis; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2004

Other Studies

2 other study(ies) available for imatinib mesylate and Acquired Immune Deficiency Syndrome

Article	Year
Growth-factor inhibition as therapy for Kaposi's sarcoma. The Lancet. Oncology, 2005, Volume: 6, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Humans; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Sarcoma, Kaposi	2005
First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents; Benzamides; Eosinophilia; Humans; Imatinib Mesylate; Male; Mastocytosis, Systemic; Monomeric GTP-Binding Proteins; Piperazines; Polymorphism, Restriction Fragment Length; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction	2006

Article

Year

Growth-factor inhibition as therapy for Kaposi's sarcoma.

The Lancet. Oncology, 2005, Volume: 6, Issue:1

Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Humans; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Sarcoma, Kaposi

2005

First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4

Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents; Benzamides; Eosinophilia; Humans; Imatinib Mesylate; Male; Mastocytosis, Systemic; Monomeric GTP-Binding Proteins; Piperazines; Polymorphism, Restriction Fragment Length; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction

2006